Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00169585
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2005-09-12
Brief Title:
Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen PSA
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A National Multicentric Randomised Controlled Trial Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multicentric national prospective parallel group controlled The Subjects in every center will be randomized and assigned to the pharmacologic arm or the one with the biochemical monitoring
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None